QIAGEN (QGEN)
(Delayed Data from NYSE)
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 5.77% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note
by Zacks Equity Research
QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.
Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?
by Moumi Mondal
Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.
Qiagen (QGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Qiagen (QGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership
by Zacks Equity Research
QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
by Moumi Mondal
Hologic's (HOLX) fundamental strength and cheaper valuation make it a great new addition to the portfolio.
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
by Zacks Equity Research
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
by Zacks Equity Research
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
by Zacks Equity Research
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
by Zacks Equity Research
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
by Zacks Equity Research
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
by Zacks Equity Research
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
QIAGEN (QGEN) to Enhance Forensics With New Partnership
by Zacks Equity Research
QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.